Bharat Covaxin
BBV152
Administration
Vaccine
- Bharat COVID-19 Vaccine. Covaxin, BBV152
Authorized for Use in
- WHO EUL, India. Meets US entry requirements.
Age
- >18 years
Type
- Inactivated whole virion.
Primary Dosing
- 2 doses (0.5 mL IM) spaced by 4 weeks.
- Moderate and severe immunocompromise: additional primary dose (dose 3) 1-3 months after dose 2
-
Three doses of mRNA vaccine is the only current effective strategy against the Omicron variant
Booster Dosing
- No recommendation
Interchangeability
- Immunogencity increased with mRNA vaccine for dose 2 compared to Bharat for dose 2.
Storage
- 2-8°C (36-46°F)
Efficacy
Overall against symptomatic disease
- 78% in Phase 3 trials pre-delta
Real world against hospitalization
- No data
Age > 60 years
- 68% in Phase 3 trials pre-delta (limited subject numbers)
Pediatric
- Not authorized
Against severe disease / death
- 93%
Against asymptomatic infection / transmission
- 63% against asymptomatic infection
Duration of efficacy after final dose
- No data
Toxicities
Contraindications
- Anaphylaxis to any vaccine component or a previous dose of Bharat vaccine.
Precautions
- No data
Not contraindications
- A history of anaphylaxis to any other vaccine or injectable therapy (i.e. intramuscular, intravenous, or subcutaneous vaccines or therapies) is not a contraindication to vaccination
Adverse effects
- Rare anaphylaxis. Local and mild systemic reactions
Special Needs Populations
Pregnancy
- Recommended for use in pregnancy. No adverse outcomes in trials or post-marketing surveillance
Immunocompromised / HIV
- Moderate and severe immunocompromise: additional primary dose (dose 3) 1-3 months after dose 2. Not needed for controlled HIV patients